WaveMan
WaveMan · Company
OMER · Omeros Corp
> Search tickers & screens ⌘K
LIVE
← All companies

OMER Omeros (OMER) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001285819
Quote by TradingView
Form 144 · 9
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
105
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $749.0K priced

What the filings say about OMER

Insiders, 180 days
-$2.3M net sold
4 sellers · 33% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$2.3M
9 notices

Omeros insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, OMEROS CORP insiders sold a net $2.3M of stock across 18 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Borges David J.
VP, Finance & CAO
SELL
2026-09-24 SECtraded 2026-09-23
10,000
$209.5K
-18.9%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Sep 22, 2026.
  • 2 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, Finance & CAO Borges David J. sold about $209.5K of OMER under a 10b5-1 plan on Sep 23, 2026; 2 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
Borges David J.
VP, Finance & CAO
SELL
2026-09-24 SECtraded 2026-09-22
10,000
$209.5K
-18.9%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 24, 2026.
  • 2 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, Finance & CAO Borges David J. sold about $209.5K of OMER under a 10b5-1 plan on Sep 22, 2026; 2 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
Cancelmo Peter B
VP, General Counsel
SELL
2026-09-01 SECtraded 2026-08-31
25,000
$463.5K
-13.6%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 28, 2026.
  • The trade is 12500.0% of the 200 shares held after it.
  • 3 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, General Counsel Cancelmo Peter B sold about $463.5K of OMER on Aug 31, 2026; 3 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
Cancelmo Peter B
VP, General Counsel
SELL
2026-09-01 SECtraded 2026-08-28
25,000
$466.1K
-13.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 12500.0% of the 200 shares held after it.
  • 3 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: VP, General Counsel Cancelmo Peter B sold about $466.1K of OMER on Aug 28, 2026, the largest insider sale at the company on our record; 3 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
HANISH ARNOLD C
Director
SELL
2026-08-28 SECtraded 2026-08-27
5,000
$94.4K
-13.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 26, 2026.
  • The trade is 100.0% of the 5,000 shares held after it.
  • 3 other insiders sold within 30 days.
  • 105 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HANISH ARNOLD C sold about $94.4K of OMER on Aug 27, 2026; 3 other insiders sold within 30 days and 105 funds added in the latest 13F quarter.
18 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 13 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.3M over 180 days
-$2.2M over 90 days
below 72% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
105 funds bought in last quarter
more than 71% of Pharma & Biotech
Revenue
-34.0% year over year
below 74% of Pharma & Biotech
Margin
-4.5% net margin
more than 70% of Pharma & Biotech
Buybacks
$9.9M repurchased, FY to 2026-06-30
below 71% of Pharma & Biotech
Short interest
16.5% of the float short (float per yahoo 2026-10-27) · 12.2 days to cover · settled 2026-10-15
more than 87% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch OMER

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+112.9%12M
-18%+46%+111%+175%2025-102025-122026-022026-042026-062026-082026-10 2026-08-28 · Cancelmo Peter B sold $466.1K2026-08-31 · Cancelmo Peter B sold $463.5K2026-01-12 · Borges David J. sold $381.6K2026-01-13 · Borges David J. sold $369.3K2026-08-20 · Cable Thomas J. sold $276.8K2026-09-22 · Borges David J. sold $209.5K2026-09-23 · Borges David J. sold $209.5K2026-08-21 · Borges David J. sold $189.5K2026-08-27 · HANISH ARNOLD C sold $95.1K2026-08-27 · HANISH ARNOLD C sold $94.4K2026-08-26 · HANISH ARNOLD C sold $92.6K2026-05-22 · Cable Thomas J. sold $87.1K2026-08-13 · Borges David J. sold $84.8K2026-08-24 · Borges David J. sold $17.3K2026-09-23 · DAVID BORGES filed to sell $314.2K2026-09-22 · DAVID BORGES filed to sell $184.9K2026-08-31 · PETER CANCELMO filed to sell $463.5K2026-08-28 · PETER CANCELMO filed to sell $466.1K2026-08-27 · ARNOLD HANISH filed to sell $189.5K2026-08-26 · ARNOLD HANISH filed to sell $94.1K2026-08-21 · DAVID BORGES filed to sell $203.2K2026-08-20 · THOMAS CABLE filed to sell $276.8K2026-08-13 · DAVID BORGES filed to sell $68.5K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns OMER: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
6,044,633 sh
$57.5M
UBS Group AG
3,148,384 sh
$29.9M
VANGUARD CAPITAL MANAGEMENT LLC
3,072,050 sh
$29.2M
STATE STREET CORP
2,319,906 sh
$22.1M
GEODE CAPITAL MANAGEMENT, LLC
1,914,460 sh
$18.2M

Congress trades in OMER

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

OMER planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
DAVID BORGES
Filed 2026-09-23
$314.2K
DAVID BORGES
Filed 2026-09-22
$184.9K
PETER CANCELMO
Filed 2026-08-31
$463.5K
PETER CANCELMO
Filed 2026-08-28
$466.1K
ARNOLD HANISH
Filed 2026-08-27
$189.5K

OMER mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$730.8K position · as of 2026-05-31
4.6%
Invesco Biotechnology & Genome ETF
$7.1M position · as of 2026-07-31
2.5%
Virtus Biotech Etf
$1.8M position · as of 2026-07-31
1.9%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$6.1M position · as of 2026-06-30
1.4%
PROFUND VP PHARMACEUTICALS
$158.9K position · as of 2026-06-30
1.4%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$272.7K position · as of 2026-07-31
1.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
10 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
6
Phase 2
3 active
2
Phase 3
0 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.2M
$17.6M
$803.5K
+660%
n/a
2024
$3.8M
$12.4M
$743.6K
+337%
n/a
2023
$7.7M
$8.7M
$853.3K
+45%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $2.3M sold by insiders over 180 days, 105 funds added last quarter, $2.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

OMER financials

Revenue growth
-34.0%
XBRL, annual
Net margin
-4.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$68.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-0.78x
TTM operating cash flow over LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion)
Return on equity
n/a
average equity is zero or negative
Return on assets
+51.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-47.4%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
9.47x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$1.3B
market value at close 2026-10-26 on 2026-08-07 shares, plus LongTermDebt as filed 2025-12-31 (6 months older than the period end) (includes the current portion), minus cash 2026-06-30
FCF yield
-5.8%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$122.8M-$167.0M-$164.5M-$163.4M
Net income-$3.4M-$156.8M-$117.8M$47.4M
EPS (diluted)-0.05-2.70-1.880.76
Operating cash flow-$116.1M-$148.8M$74.7M-$86.5M
Cash$9.7M$3.4M$7.1M$11.0M
Long-term debt$87.9M$164.9M$213.2M$315.3M
Buybacks$0$11.9M$4.7M$0
SEC XBRL, fiscal years, as known on 2026-10-28

OMER Stock Sonar score 6/7 axes

Find similar shapesCompare

OMER ranks highest on profitability (75th percentile) and institutional and government (58th), and lowest on insider conviction (15th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
75
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets+51.2% · 96 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-47.4% · 53 pct, sector of 576
Financial health
56
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-0.78x · 56 pct, sector of 371
Growth
26
Inputs
  • Revenue growth, YoY-34.0% · 26 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
15
Inputs
  • Net Form 4 buying (codes P and S), 180d-$1.7M · 30 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
58
Inputs
  • Funds adding, latest quarter105 · 71 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$210K · 45 pct, sector of 133
Risk and compliance
16
Inputs
  • Short interest, % of float+16.5% · 21 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+22.7% · 12 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

OMER filings, in plain words

Are Omeros insiders buying or selling OMER?

In the 180 days to 2026-10-28, Omeros insiders were net sellers, a net $2.3M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of OMER?

Yes. 9 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $2.3M of stock; the latest, by DAVID BORGES, was filed 2026-09-23.

Read the full summary

In the 180 days to 2026-10-28, Omeros insiders were net sellers of OMER, a net $2.3M across purchases and sales reported on Form 4 by 4 sellers. 33% of the 12 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 9 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $2.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies